United Therapeutics reports Q3 2026 earnings miss despite revenue beat
United Therapeutics posted Q3 2026 adjusted earnings of $5.71 per share, falling short of the $6.21 consensus by $0.50. Revenue rose 4% year‑over‑year to $832.5 million, topping the $785.44 million estimate. The earnings shortfall was driven by a 119% surge in R&D spending, largely for the Thymmune Therapeutics acquisition. The board also approved a new $2.0 billion share‑repurchase program through October 2027.
Why it matters
The EPS miss caused the stock to decline 3.11% after the release. The revenue beat may support the company’s growth narrative, but the higher R&D outlay and lower margin could pressure profitability going forward.
Key facts
- 1Q3 2026 revenue was $832.5 million, up 4% YoY. tradingview.com
- 2Adjusted earnings per share were $5.71, missing the $6.21 consensus by $0.50. investing.com
- 3Research and development expenses rose to $279.2 million, a 119% increase from the prior year quarter. investing.com
- 4The company repurchased 980,394 shares of common stock during the quarter. investing.com
- 5The board approved a $2.0 billion share‑repurchase program through October 2027. tradingview.com
- 6Shares fell 3.11% following the earnings release. investing.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.